These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 26272554)
41. Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys. Mifsud EJ; Tan AC; Brown LE; Chua BY; Jackson DC Front Immunol; 2015; 6():290. PubMed ID: 26097481 [TBL] [Abstract][Full Text] [Related]
42. Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration. Patil HP; Murugappan S; de Vries-Idema J; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A Eur J Pharm Biopharm; 2015 Jun; 93():231-41. PubMed ID: 25896446 [TBL] [Abstract][Full Text] [Related]
43. Intranasal immunization of mice with inactivated virus and mast cell activator C48/80 elicits protective immunity against influenza H1 but not H5. Xu L; Bao L; Li F; Lv Q; Yuan J; Xu Y; Deng W; Yao Y; Yu P; Qin C Immunol Invest; 2014; 43(3):224-35. PubMed ID: 24295504 [TBL] [Abstract][Full Text] [Related]
45. Red ginseng and vitamin C increase immune cell activity and decrease lung inflammation induced by influenza A virus/H1N1 infection. Kim H; Jang M; Kim Y; Choi J; Jeon J; Kim J; Hwang YI; Kang JS; Lee WJ J Pharm Pharmacol; 2016 Mar; 68(3):406-20. PubMed ID: 26898166 [TBL] [Abstract][Full Text] [Related]
46. Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice. Nosaka N; Yashiro M; Yamada M; Fujii Y; Tsukahara H; Liu K; Nishibori M; Matsukawa A; Morishima T Crit Care; 2015 Jun; 19(1):249. PubMed ID: 26067826 [TBL] [Abstract][Full Text] [Related]
47. A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate. Zeng W; Tan AC; Horrocks K; Jackson DC Vaccine; 2015 Jul; 33(30):3526-32. PubMed ID: 26049002 [TBL] [Abstract][Full Text] [Related]
48. Select targeting of intracellular Toll-interleukin-1 receptor resistance domains for protection against influenza-induced disease. Shirey KA; Lai W; Brown LJ; Blanco JCG; Beadenkopf R; Wang Y; Vogel SN; Snyder GA Innate Immun; 2020 Jan; 26(1):26-34. PubMed ID: 31955622 [TBL] [Abstract][Full Text] [Related]
49. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. Quan FS; Huang C; Compans RW; Kang SM J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294 [TBL] [Abstract][Full Text] [Related]
50. Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus. Ichinohe T; Nagata N; Strong P; Tamura S; Takahashi H; Ninomiya A; Imai M; Odagiri T; Tashiro M; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H J Med Virol; 2007 Jun; 79(6):811-9. PubMed ID: 17457919 [TBL] [Abstract][Full Text] [Related]
52. Development of Zhou Y; Banday AH; Hruby VJ; Cai M Molecules; 2019 Sep; 24(19):. PubMed ID: 31569697 [TBL] [Abstract][Full Text] [Related]
53. Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines. Lu BL; Williams GM; Verdon DJ; Dunbar PR; Brimble MA J Med Chem; 2020 Mar; 63(5):2282-2291. PubMed ID: 31418565 [TBL] [Abstract][Full Text] [Related]
54. Testosterone treatment of aged male mice improves some but not all aspects of age-associated increases in influenza severity. Vom Steeg LG; Attreed SE; Zirkin B; Klein SL Cell Immunol; 2019 Nov; 345():103988. PubMed ID: 31540670 [TBL] [Abstract][Full Text] [Related]
55. Immune Modulation to Improve Survival of Viral Pneumonia in Mice. Wali S; Flores JR; Jaramillo AM; Goldblatt DL; Pantaleón García J; Tuvim MJ; Dickey BF; Evans SE Am J Respir Cell Mol Biol; 2020 Dec; 63(6):758-766. PubMed ID: 32853024 [TBL] [Abstract][Full Text] [Related]
56. Depletion of microglia and macrophages with clodronate liposomes attenuates zymosan-induced Fos expression and hypothermia in the adult mouse. Takagi S; Murayama S; Torii K; Takemura-Morita S; Kurganov E; Nagaoka S; Wanaka A; Miyata S J Neuroimmunol; 2020 Jul; 344():577244. PubMed ID: 32330748 [TBL] [Abstract][Full Text] [Related]
57. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity. Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227 [TBL] [Abstract][Full Text] [Related]
58. Prospects on Repurposing a Live Attenuated Vaccine for the Control of Unrelated Infections. Seo SU; Seong BL Front Immunol; 2022; 13():877845. PubMed ID: 35651619 [TBL] [Abstract][Full Text] [Related]